Back to Search
Start Over
Additional Evidence for Commonalities between COVID-19 and Radiation Injury: Novel Insight into COVID-19 Candidate Drugs.
- Source :
-
Radiation research [Radiat Res] 2022 Sep 01; Vol. 198 (3), pp. 306-317. - Publication Year :
- 2022
-
Abstract
- COVID-19 is a challenge to biosecurity and public health. The speed of vaccine development lags behind that of virus evolution and mutation. To date, no agent has been demonstrated to be fully effective against COVID-19. Therefore, it remains of great urgency to rapidly develop promising therapeutic and diagnostic candidates. Intriguingly, mounting evidence hints at parallel etiologies between SARS-CoV-2 infection and radiation injury. Herein, from the perspectives of immunogenic pathway activation and metabolic alterations, we provide novel evidence of commonalities between these two pathological conditions based on the most recent findings. Since numerous agents have been developed to prevent or reverse radiation injury in the past 70 years to ensure nuclear safety, we also advocate investigating the promising function of radioprotectors and radiomitigators against COVID-19 in clinical settings.<br /> (©2022 by Radiation Research Society. All rights of reproduction in any form reserved.)
- Subjects :
- Humans
SARS-CoV-2
COVID-19
Radiation Injuries
Subjects
Details
- Language :
- English
- ISSN :
- 1938-5404
- Volume :
- 198
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- Radiation research
- Publication Type :
- Academic Journal
- Accession number :
- 35834824
- Full Text :
- https://doi.org/10.1667/RADE-22-00058.1